Akorn, Inc. (AKRX)
(Real Time Quote from BATS)
$12.88 USD
-6.82 (-34.62%)
Updated Apr 23, 2018 03:48 PM ET
5-Strong Sell 5
D Value | F Growth | D Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.71% |
| 2 | Buy | 18.12% |
| 3 | Hold | 9.91% |
| 4 | Sell | 5.49% |
| 5 | Strong Sell | 2.29% |
| S&P | 500 | 9.79% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Is the Options Market Predicting a Spike in Akorn (AKRX) Stock?
by Zacks Equity Research
Investors in Akorn (AKRX) need to pay close attention to the stock based on moves in the options market lately.
AKRX
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.
UCBJF AZN SHPG NVS AGN SNY MRK PFE MNKD GSK PBYI MKGAF GERN IONS OSIR OREXQ INCY BIIB NVO RHHBY REGN LLY MYL ACOR BAYRY ABT ABBV ARNA AMGN ALKS ESRX BMY AKRX VRX ENDP
Pharma Industry Outlook: M&A, Licensing Abound
by Arpita Dutt
Looking at consensus earnings expectations for the fourth quarter, earnings are expected to grow 16.3% and revenues 8.9%. New product sales should pick up significantly going forward.
UCBJF AZN SHPG NVS TEVA AGN SNY MRK PFE GSK MKGAF INCY ICPT RHHBY LLY NVLN MYL ACHN ABT ABBV AMGN BMY AKRX VRX ENDP
Stocks with Upgraded Broker Ratings
by Kevin Matras
Kevin Matras explains why looking for stocks with upgraded broker ratings can upgrade your portfolio to a whole new level. Highlighted stocks include CAM, MU, AKRX, JLL and DTSI.
JLL MU AKRX
Market-Caps and Stock Selection for Maximum Gains
by Kevin Matras
Small-cap stocks are often market leaders, but don't overlook the mid-caps and large-caps. See how that leadership has changed over the years and which one is in the lead now.
SIMO SEE ODFL ICLR LABL AKRX
Bull of the Day: Akron Inc (AKRX)
by Brian Bolan
A solid recent beat and a growing short position imply a good chance for a short squeeze.
AKRX
Using the Short Ratio to Forecast Turning Points
by Kevin Matras
Kevin Matras looks at the 'short ratio' as a market sentiment indicator and shows how to use it for finding winning stocks. Highlighted stocks include ZINC, ENPH, AKRX, TPH and INT.
TPH INT AKRX ENPH
Akorn, Inc.
by Jared Levy
This small-cap pharmaceutical company has outpaced the S&P 500 by over 122% this year. They recently announced that Q4 earnings were going to exceed expectations. Akorn might be worth a look.
AKRX
Increasing Volume to Uncover Institutional Buying
by Kevin Matras
Kevin Matras shows how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include AKRX, DSX, ENDP, LUV and UNH.
UNH LUV DSX AKRX ENDP
Akorn, Inc
by Bill Wilton
Analysts still love AKRX.
AKRX
Akorn, Inc
by Bill Wilton
AKRX is generating excellent growth both organically and through M&A activity.
AKRX